trending Market Intelligence /marketintelligence/en/news-insights/trending/1kyuO1U7V2Fai0TY8PbqwQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Rhythm Pharmaceuticals raises $172.5M from offering of common shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Rhythm Pharmaceuticals raises $172.5M from offering of common shares

Rhythm Pharmaceuticals Inc. raised about $172.5 million in gross proceeds from a public offering of common shares.

The Boston-based biotechnology company sold 9,324,324 common shares in the offering at $18.50 apiece, including the 1,216,216 common shares the offering's underwriters acquired as part of their overallotment option.

Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC and Cowen and Co. LLC were acting as joint book-running managers for the offering, while Needham & Co. LLC was the lead manager.

Rhythm Pharmaceuticals develops therapies for rare genetic disorders that result in life-threatening metabolic disorders. In August, its experimental drug setmelanotide reduced body weight and insatiable hunger in patients with two rare types of genetic obesity, the main goals of two late-stage trials.